Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc. (KLDO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · KLDO · as of Mar 31, 2025
Ownership Breakdown
1
Institutional Holders
▲ 1 vs Q4
$2
Total Inst. Value
▲ $2 vs Q4
42.62M
Shares Outstanding
freeFloat 99.59%
2,300
13F Shares Held
▲ 2,300 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
KLDO largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 1 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAY HARBOR WEALTH MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.3K | 0.55% | 0.55% | $2,000 | May 12, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
0
Increased
+0 shares1
New Positions
first time holders0
Decreased
−0 shares0
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
+1
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
KLDO insider trading · insider activity
Source: SEC Form 4
9
Buy transactions
2
Sell transactions
4.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
van Hylckama Vlieg Johan Chief Scientific Officer | Feb 28, 2022 | Tax Withhold | 2,087 | $1.49 | $3.1K | 4.6K | Form 4 ↗ |
Korn Jerald COO & General Counsel | Feb 28, 2022 | Tax Withhold | 2,046 | $1.49 | $3.0K | 4.5K | Form 4 ↗ |
van Hylckama Vlieg Johan Chief Scientific Officer | Jan 14, 2022 | Award | 350,000 | — | — | 350.0K | Form 4 ↗ |
Long Alison S Chief Medical Officer | Jan 14, 2022 | Award | 125,000 | — | — | 125.0K | Form 4 ↗ |
Long Alison S Chief Medical Officer | Jan 14, 2022 | Award | 46,800 | — | — | 46.8K | Form 4 ↗ |
Korn Jerald COO & General Counsel | Jan 14, 2022 | Award | 250,000 | — | — | 250.0K | Form 4 ↗ |
Korn Jerald COO & General Counsel | Jan 14, 2022 | Award | 45,240 | — | — | 45.2K | Form 4 ↗ |
Duke William E. Chief Financial Officer | Jan 14, 2022 | Award | 125,000 | — | — | 125.0K | Form 4 ↗ |
Duke William E. Chief Financial Officer | Jan 14, 2022 | Award | 44,990 | — | — | 45.0K | Form 4 ↗ |
Menichella Daniel L Chief Executive Officer | Jan 14, 2022 | Award | 250,000 | — | — | 250.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Kaleido Biosciences, Inc. (KLDO) is primarily owned by institutional investors, who hold approximately 0.0% of total shares outstanding. Company insiders own approximately 0.41%, while retail and public investors account for the remaining 99.58%.
The largest institutional shareholder of Kaleido Biosciences, Inc. is BAY HARBOR WEALTH MANAGEMENT, LLC, holding approximately 2,300 shares — equal to 0.55% of outstanding shares — as of March 31, 2025.
A total of 1 institutional investors currently hold KLDO stock, with a combined institutional value of approximately $2 as of the most recent 13F filing period.
Frequently asked questions
KLDO ownershipKaleido Biosciences, Inc. (KLDO) is primarily owned by institutional investors, who hold approximately 0.0% of shares. The largest shareholder is BAY HARBOR WEALTH MANAGEMENT, LLC with a 0.55% stake. Company insiders hold 0.41%. Data sourced from SEC Form 13F as of March 31, 2025.